Midlands Independent Review Board Chairperson Dr. Kathy Chase to Speak at 2014 American College of Clinical Pharmacology Annual Meeting
PRINCETON, N.J., Sept. 16, 2014 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services for clinical research, announced today that Kathy Chase, PharmD, chairperson of Midlands Independent Review Board (IRB), will speak at the American College of Clinical Pharmacology (AACP) Annual Meeting being held Sept. 14-16 in Atlanta, GA.
Dr. Chase will participate in a symposium entitled, “Key Considerations for Efficient Study Designs in Early Stage Clinical Development and Proof-of-Concept Studies.” Specifically, she will address, “IRB Considerations: Approving Protocols with Healthy Normal Volunteers/Special Populations and Overall Subject Safety.” During this symposium, the group will focus on ways to implement best practices for designing a clinical development program that encompasses preclinical studies. The presentation will take place on Tuesday, Sept. 16 at 8:00 am EDT.
“When special populations are involved in a study protocol, the duty of the IRB is increased,” said Donald A. Deieso, Ph.D., WCG’s chairman and CEO. “It is imperative that we educate our peers on the explicit manner in which we should protect special populations involved in clinical trials. Dr. Chase has the expertise and insight to properly inform our industry of best practices when approving such protocols.”
As Chairperson of the Midlands IRB Board, Dr. Chase oversees IRB Board activities and provides regulatory guidance to the company. She brings 24 years of IRB-related experience and service to her role.
Earlier this year, Midlands IRB joined the WCG family of companies, expanding the Group’s presence in the Kansas City, MO clinical research hub and increasing its expertise in Early Phase (I & II) reviews.
For more information about this year’s AACP meeting, please visit: http://www.accp1.org/2014_meetings_welcome.shtml.
About The WIRB-‐Copernicus Group
The WIRB-Copernicus Group (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.
WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.
For more information, please visit www.wcgclinical.com.
Download the Press Release